US2020268772A1PendingUtilityA1

Hiv maturation inhibitor formulations

38
Assignee: VIIV HEALTHCARE UK (NO4) LTDPriority: Nov 20, 2015Filed: Nov 18, 2016Published: Aug 27, 2020
Est. expiryNov 20, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Albert J. DelmonteIra B. DickerCarey K. HwangSamit Ramesh JoshiMax Lataillade
A61K 31/58A61P 31/18A61K 31/5365A61K 31/4418A61K 2300/00A61K 31/427
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Co-formulations of HIV maturation inhibitor compound with one or two other HIV compounds, and methods of treatment, are set forth.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A two drug formulation of antiretroviral drugs useful against HIV, comprising dolutegravir and a maturation inhibitor selected from the group of: 
       
         
           
           
               
               
           
         
       
     
     
         17 . A two drug formulation of antiretroviral drugs useful against HIV, comprising atazanavir and a maturation inhibitor selected from the group of: 
       
         
           
           
               
               
           
         
       
     
     
         18 . The formulation of  claim 17 , wherein said atazanavir is unboosted. 
     
     
         19 . The formulation of  claim 17 , wherein said atazanavir is boosted with ritonavir. 
     
     
         20 - 27 . (canceled) 
     
     
         28 . A method of treating HIV infection, comprising administering to a patient in need the formulation as claimed in  claim 16 . 
     
     
         29 . (canceled)

Join the waitlist — get patent alerts

Track US2020268772A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.